DURECT has filed a patent for a method of treating autoimmune conditions such as hepatitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. The method involves administering specific compounds to the subject, which may be associated with Epstein-Barr virus infection. GlobalData’s report on DURECT gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on DURECT, Nanoparticle drug conjugates was a key innovation area identified from patents. DURECT's grant share as of September 2023 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Treating autoimmune conditions using specific compounds
A recently filed patent (Publication Number: US20230293551A1) describes a method for treating autoimmune conditions in individuals. The method involves administering specific compounds to the subject, which may be associated with Epstein-Barr virus infection. The compounds mentioned in the patent include 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesteroldisulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesteroldisulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesteroldisulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or their salts.
The patent claims that the method can be used to treat various autoimmune conditions, including hepatitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. It also specifies that the method can be used for autoimmune conditions associated with Epstein-Barr virus infection.
The patent further provides details on the administration of the compounds. The compounds can be administered in different amounts, ranging from 0.001 mg/kg/day to 100 mg/kg/day, depending on the body mass of the subject. The administration can be performed once to three times per day, and it can be done through various routes such as oral, enteric, sublingual, transdermal, intravenous, peritoneal, parenteral, injection (subcutaneous or intramuscular), among others.
The compounds can be formulated into a pharmaceutical composition with a physiologically acceptable excipient, diluent, or carrier. The composition can be in solid form, such as powder, tablet, capsule, or lozenge, and it may also include a bulking agent. Alternatively, the composition can be in liquid form, with the compounds solubilized or dispersed in an aqueous or sterile liquid, such as sterile water for injections or phosphate-buffered saline. The pharmaceutical composition can be packaged in a sealed vial, ampoule, syringe, or bag.
It is important to note that the information provided is based solely on the claims made in the filed patent and does not include any additional data or research findings.
To know more about GlobalData’s detailed insights on DURECT, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
